Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 88Rituximab 76Specimen Handling 75Magnetic Resonance Spectroscopy 64Biopsy 60Vincristine 49Doxorubicin 48Prednisone 45venetoclax 38obinutuzumab 34fludarabine 32Lenalidomide 29ibrutinib 28Cytarabine 27Dexamethasone 26Methotrexate 25prednylidene 23Etoposide 23zanubrutinib 22deltacortene 22CT-P10 22blinatumomab 21acalabrutinib 21Nivolumab 21fludarabine phosphate 19merphos 18Bendamustine Hydrochloride 17Calcium Dobesilate 16pembrolizumab 15X-Rays 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
EPOCH protocol × Lymphoid × 30 days × Clear all
NCT04002947 2026-06-03

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
132 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡